Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Cimetidine: Mechanism, Evidence, and Research Integration

    2026-01-05

    Cimetidine: Mechanism, Evidence, and Research Integration

    Executive Summary: Cimetidine (SKU B1557, APExBIO) is a histamine-2 (H2) receptor antagonist and partial agonist with a unique pharmacological profile distinct from other H2 antagonists such as ranitidine and famotidine (APExBIO). It exhibits antitumor activity in gastrointestinal cancers, attributed to its modulation of H2 receptor signaling pathways (related article). The compound is highly soluble in DMSO (≥12.62 mg/mL), ethanol (≥9.37 mg/mL), and water (≥2.54 mg/mL), facilitating diverse experimental workflows. Its purity (approx. 98%) is verified by HPLC and NMR, supporting reproducible research outcomes. Cimetidine’s use in advanced blood-brain barrier (BBB) models enables early-stage screening of CNS drug candidates (Hu et al., 2025).

    Biological Rationale

    Cimetidine is used in research as a selective histamine-2 (H2) receptor antagonist and partial agonist. The H2 receptor plays central roles in regulating gastric acid secretion and modulating immune signaling. Cimetidine’s dual action enables detailed study of H2R-associated pathways, including the suppression of gastric acid and the potential inhibition of tumor growth in gastrointestinal tissues. Its molecular weight is 252.34 g/mol, and the chemical name is 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine (APExBIO). Cimetidine’s high solubility in multiple solvents (DMSO, water, ethanol) and stability at -20°C make it well-suited for both in vitro and in vivo experimental designs. The purity, validated by HPLC and NMR analyses, ensures minimal off-target effects and reliable data interpretation.

    Mechanism of Action of Cimetidine

    Cimetidine competitively inhibits histamine binding at the H2 receptor, thereby reducing gastric acid secretion from parietal cells. Unlike ranitidine and famotidine, Cimetidine functions as a partial agonist, which allows for nuanced modulation of H2 receptor signaling (see Redefining Cimetidine; this article expands on the mechanistic contrast by linking to high-throughput CNS model applications). This unique activity profile underpins its use as a probe compound in studies of signal transduction, receptor pharmacology, and tumor cell biology. In cancer research, Cimetidine’s antagonism of H2R is associated with reduced tumor proliferation and enhanced immune-mediated cytotoxicity, particularly in gastrointestinal cancer models. Additionally, Cimetidine’s documented permeability properties allow investigation within blood-brain barrier platforms for CNS drug development (Hu et al., 2025).

    Evidence & Benchmarks

    • Cimetidine’s antagonistic action at the H2 receptor reduces basal and stimulated gastric acid secretion in vitro and in vivo (Hu et al., 2025).
    • Partial agonist properties differentiate Cimetidine from ranitidine and famotidine, enabling unique receptor modulation (related analysis).
    • In high-throughput BBB models (LLC-PK1-MOCK/MDR1 cells), Cimetidine’s permeability and efflux characteristics can be quantified, supporting CNS drug screening (Hu et al., 2025).
    • Cimetidine is highly soluble: ≥12.62 mg/mL in DMSO, ≥2.54 mg/mL in water (with warming and ultrasound), and ≥9.37 mg/mL in ethanol (APExBIO).
    • Purity is approximately 98%, confirmed by HPLC and NMR, ensuring experimental reproducibility (see Scientific Solutions guide—this article extends by detailing CNS workflow integration).
    • Antitumor activity is observed in gastrointestinal cancer models, linked to H2R antagonism and immune modulation (advanced pharmacological profile).

    Applications, Limits & Misconceptions

    Cimetidine is widely used in:

    • Cell-based assays for viability, proliferation, and cytotoxicity (reliable solutions guide; this article clarifies recent advances in workflow robustness).
    • Gastric acid secretion studies in gastrointestinal models.
    • Antitumor mechanism research, especially in gastrointestinal cancers.
    • Blood-brain barrier permeability and CNS drug development workflows (Hu et al., 2025).

    Common Pitfalls or Misconceptions

    • Cimetidine is not approved for diagnostic or medical use; it is intended strictly for scientific research (APExBIO).
    • Long-term storage of Cimetidine solutions is discouraged; short-term use is recommended to maintain stability.
    • Partial agonist activity can confound interpretation if compared directly with pure antagonists; matching conditions is essential.
    • Cimetidine’s BBB permeability may differ in vivo due to lysosomal trapping or transporter effects—interpret CNS data with validated models (Hu et al., 2025).
    • Purity below 98% (as confirmed by HPLC/NMR) may result in experimental variability.

    Workflow Integration & Parameters

    For research workflows, Cimetidine (APExBIO, SKU B1557) is supplied as a solid with approximately 98% purity. Prepare stock solutions in DMSO, ethanol, or water as needed; for water, use gentle warming and ultrasonic treatment. Store the compound at -20°C for optimal stability. Solutions should be freshly prepared and used within a short period to avoid degradation. Its compatibility with both cell-based and biochemical assays facilitates integration into high-throughput screening, signal transduction studies, and blood-brain barrier permeability assays. Cimetidine’s performance in LLC-PK1-MOCK/MDR1 BBB models enables early prioritization of CNS-active candidates (Hu et al., 2025).

    Conclusion & Outlook

    Cimetidine’s dual role as a histamine-2 receptor antagonist and partial agonist, together with its high solubility and purity, enables robust and reproducible research in cancer biology and CNS drug development. APExBIO’s validated Cimetidine product supports rigorous experimental workflows. Ongoing advances in blood-brain barrier modeling and high-throughput screening continue to expand Cimetidine’s utility for early-stage drug discovery. For further mechanistic insights and comparative guidance, see Redefining Cimetidine: Mechanistic Insights (this article updates prior mechanistic focus with structured CNS and workflow integration).